Stevanato Group (STVNN) AI Stock Analysis

Stevanato Group

(BMV:STVNN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High-value solutions growthRapid growth in high-value solutions is improving Stevanato’s product mix and deepening its role in biologics and premium injectable therapies. A larger share of specialized offerings can support recurring customer relationships, stronger differentiation, and better long-term earnings quality.

Negative Factors

Weak free-cash-flow conversionPositive operating cash flow is not currently translating into free cash flow because capital spending and working-capital needs are absorbing cash. Persistent volatility or deficits would reduce funding flexibility, increase reliance on financing, and make growth investments harder to self-finance.

Stevanato Group (STVNN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 5.29B
Dividend Yield: 0.30%
Average Volume (3M): ―
Price to Earnings (P/E): 36.1
Beta (1Y): 0.04
Revenue Growth: 4.63%
EPS Growth: -1.68%
Country: Mexico
Employees: 6,010
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Stevanato Group Business Overview & Revenue Model

Company Description

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery s...

Stevanato Group Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:20.52%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.

Positive Updates

Revenue Growth

Total revenue grew 8% year-over-year to EUR 302.0 million in Q2 2026 (reported and constant currency). Growth was driven by the Biopharmaceutical & Diagnostic Solutions (BDS) segment, which rose 9% to EUR 266.2 million.

Negative Updates

One-Time Divestiture Costs and Revenue Removal

Completed sale of U.S. subsidiary Balda C. Brewer generated one-time transaction expenses of EUR 12.2 million in Q2 2026. The divested subsidiary had been expected to generate approximately EUR 30 million of revenue in fiscal 2026; the company factored a revenue reduction of ~EUR 15 million into updated guidance.

Company Guidance

Management updated full‑year 2026 guidance to revenue of €1.260–€1.280 billion (reflecting ~€15m less from the Balda C. Brewer divestiture), adjusted EBITDA of €335–€345.2m (center point implying an adjusted EBITDA margin of ~26.8%, about +170 bps year‑over‑year), and adjusted diluted EPS of €0.60–€0.62; high‑value solutions are expected to make up 47–48% of revenue. Segment assumptions: BDS is expected to grow reported high single digits (organic growth remains double‑digit after currency and divestiture adjustments) while Engineering is expected to decline mid‑single digits to low‑double digits. Cash‑flow and tax guidance: free cash flow is forecast between breakeven and +€20m and an adjusted tax rate of ~28.2% (partly offset by lower‑than‑anticipated depreciation, amortization and financial expenses); the divestiture is expected to be accretive to full‑year margins.

Stevanato Group Risk Analysis

Stevanato Group disclosed 64 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Our use of new and evolving technologies, such as artificial intelligence, may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.Q4, 2025

Stevanato Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:STVNN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	78Outperform	$28.74B	46.00	21.08%	0.21%	12.60%	32.05%
ATR	67Neutral	$8.72B	32.98	10.14%	1.40%	8.97%	-34.33%
ICUI	65Neutral	$4.10B	136.48	1.41%	―	-8.84%	―
BDX	63Neutral	$53.90B	59.60	3.79%	2.01%	-2.56%	-40.38%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	45Neutral	$11.90B	-16.67	-11.62%	0.17%	5.33%	-164.67%

* Healthcare Sector Average

Performance Comparison

MX:STVNN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:STVNN	Stevanato Group Spa	349.52	-93.44	-21.09%
ATR	AptarGroup, Inc.	137.20	25.35	22.67%
BAX	Baxter International Inc	23.00	4.83	26.55%
BDX	Becton, Dickinson and Co	197.88	61.95	45.57%
ICUI	ICU Medical	163.78	40.92	33.31%
WST	West Pharmaceutical Services, Inc.	412.62	133.71	47.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Stevanato Group AI Stock Analysis